Ivosidenib as maintenance therapy for IDH1-mutated AML or high-risk MDS in patients ineligible for transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2 interventional trial evaluating ivosidenib as a maintenance therapy for adults with IDH1-mutated AML or high-risk MDS who are not eligible for allogeneic stem cell transplantation. Participants who achieve complete or partial remission after induction will receive ivosidenib until disease progression or unacceptable toxicity. The study also includes molecular biomarker research to understand treatment effects and resistance. Safety and efficacy data will inform whether maintenance therapy with ivosidenib can prolong remission in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years, male or female.
* Molecularly confirmed diagnosis of IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
* Achieved complete remission (CR) or partial remission (PR) after induction therapy.
* Ineligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT).
* Eastern Cooperative Oncology Group (ECOG) performance status score ≤2.
* Signed informed consent.
* For women of childbearing potential: must have practiced contraception for at least one month prior to screening and commit to using contraception throughout the study period and for the required period after study completion.
* Female participants of childbearing potential and male participants with female partners of childbearing potential must agree to use highly effective methods of contraception from the time of signing informed consent until 180 days after the last dose of the study drug.

Exclusion Criteria:

Participants with any of the following criteria will be excluded from the study:

* Prior treatment with an IDH1 inhibitor.
* Diagnosis of M3 subtype (acute promyelocytic leukemia, APL).
* Presence of severe hepatic or renal dysfunction.
* Active infection or other serious comorbidities.
* Major surgery within 28 days prior to the first dose, or planned surgery during the study period.
* Diagnosis of any other malignancy within 5 years prior to the first dose, with the exception of early-stage malignancies that have been cured by radical treatment, such as carcinoma in situ of the lung, non-melanoma skin cancer, basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ. Whether to exclude such patients will be determined by the investigator's assessment.
* Severe cardiovascular disease, such as New York Heart Association (NYHA) class 2 heart failure, unstable angina, unstable arrhythmia, myocardial infarction or cerebrovascular accident within 3 months prior to randomization.
* Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); active hepatitis B (HBV DNA≥1000 IU/ml); hepatitis C (positive for anti-HCV antibodies and HCV-RNA above the lower limit of detection of the assay); or co-infection with hepatitis B and hepatitis C.
* Known history of psychoactive substance abuse or drug addiction.
* Presence of any other serious physical or mental illness, or abnormal laboratory findings that may increase the risk of study participation, interfere with the study results, or make the patient unsuitable for study participation in the opinion of the investigator.
* Inability to swallow, intestinal obstruction, or other factors affecting drug administration or absorption.
* Previous concomitant treatment with both drugs of the combination therapy targeting the same pathway as in this study.
* History of allergy to the study drug or any of its excipients.

Where it's running

• Ruijin Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Sujiang Zhang
• Email: zbruce.zhang@hotmail.com
• Phone: 86-21-64370045 ext 788755

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Haplo-cord Blood Transplant for AML and high-risk MDS

  This study tests a haploidentical-cord blood stem cell transplant approach in patients with AML or high-risk MDS to see how different engraftment patterns affect outcomes.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian and 3 other locations · NCT07588360

• Wearable monitoring to collect health data in people receiving transfusions for blood cancers

  This project will try a wrist-worn accelerometer to see if continuous activity and symptom tracking helps doctors understand and support adults with MDS, AML or related blood cancers who need transfusions.

  Recruiting University of Oxford · Oxford, OXFORDSHIRE · NCT07511829

• Treosulfan vs Melphalan conditioning before allogeneic transplant in AML/MDS

  In this study, adults with AML or MDS who are getting an allogeneic transplant try two different conditioning regimens (Treosulfan or Melphalan) to see which one works better and is easier to tolerate.

  Recruiting at 16 sites Phase 2 Technische Universität Dresden · Aachen and 16 other locations · NCT07025824

• Interferon-α Maintenance for Favorable-Risk AML

  This study tests pegylated interferon alfa-2b as maintenance therapy to see if it helps keep favorable-risk AML in remission after initial treatment.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07925554

• CARCIK-CD123/33 cells for relapsed or refractory AML and BPDCN in children and adults

  This trial tests CARCIK-CD123/33 cell therapy to see if it is safe and feasible for people with relapsed or refractory AML or BPDCN, including kids and adults, before planned stem cell transplant.

  Recruiting Phase 1/2 Fondazione Matilde Tettamanti Menotti De Marchi Onlus · Monza, MB and 1 other locations · NCT07877610

• Soursop tea in relapsed/refractory AML or multiple myeloma

  This pilot study tests whether drinking tea made from soursop leaves can help reduce cancer cells in people with relapsed or refractory AML or MM.

  Recruiting Early Phase 1 Cooper Norcross Health · Camden, New Jersey · NCT07771803

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.